Zepbound Complete Drug-Drug Interaction Profile

How Tirzepatide Works and Why Gastric Emptying Defines Its Interaction Profile

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It binds both receptors simultaneously, producing greater glycemic control and weight loss than selective GLP-1 receptor agonists alone 1. In SURMOUNT-1 (N=2,539), participants on tirzepatide 15 mg lost 20.9% of body weight at 72 weeks compared with 3.1% in the placebo group 1.

The interaction profile of Zepbound is defined almost entirely by one pharmacological effect: delayed gastric emptying. GLP-1 receptor activation slows pyloric relaxation and reduces antral contractility, keeping oral medications in the stomach longer than expected 2. This delay reduces the peak concentration (Cmax) and extends the time to peak concentration (Tmax) of co-administered oral drugs.

Tirzepatide does not inhibit or induce cytochrome P450 enzymes 3. This distinguishes it from drugs like fluconazole or rifampin, where hepatic enzyme competition drives most interactions. The FDA prescribing information states: "Tirzepatide delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications" 3. Every clinically relevant interaction with Zepbound traces back to this single mechanism.

Oral Contraceptives Require a Backup Method

The FDA flagged this interaction prominently because of its direct patient-safety implication. In a dedicated pharmacokinetic study, a single dose of a combined oral contraceptive (containing 0.035 mg ethinyl estradiol and 0.25 mg norgestimate) was administered before and during tirzepatide treatment 3. After the first tirzepatide injection, ethinyl estradiol Cmax dropped by up to 55% and Tmax was delayed by approximately 3.5 hours 4.

At steady state (after multiple tirzepatide doses), the magnitude of this effect decreased but did not disappear. Ethinyl estradiol Cmax was still reduced by roughly 18% to 22% 4. Norgestimate's active metabolite, norelgestromin, showed similar patterns.

The prescribing information recommends that patients using oral hormonal contraceptives "switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation step" 3. This is not a suggestion. A 55% reduction in estrogen peak concentration can push hormone levels below the threshold needed to suppress ovulation reliably. Patients who cannot switch to a patch, ring, IUD, or implant should use condoms during those windows.

Insulin and Sulfonylureas: Mandatory Dose Adjustments

Tirzepatide amplifies endogenous insulin secretion in a glucose-dependent manner through both GIP and GLP-1 receptor pathways 5. When exogenous insulin or a sulfonylurea is already on board, the combined insulin load creates a substantial hypoglycemia risk.

In the SURPASS clinical trial program, which studied tirzepatide in type 2 diabetes, hypoglycemia rates were highest in arms where patients co-administered sulfonylureas or basal insulin. SURPASS-4 (N=2,002) reported clinically significant hypoglycemia (blood glucose <54 mg/dL) in 0.5% to 1.5% of tirzepatide-treated participants using concomitant sulfonylureas, compared with 0.4% on insulin glargine alone 6.

The FDA label requires a dose reduction of co-administered insulin or sulfonylurea when starting Zepbound 3. No fixed percentage is specified because the right reduction depends on baseline HbA1c, current insulin dose, and renal function. A common clinical approach: reduce basal insulin by 20% at tirzepatide initiation, then titrate based on fasting glucose readings over 2 to 4 weeks. Sulfonylurea doses are typically halved or discontinued.

Patients should increase self-monitoring of blood glucose frequency during the first 8 to 12 weeks of overlapping therapy. This risk diminishes once tirzepatide doses stabilize.

Acetaminophen: The Gastric Emptying Benchmark

Acetaminophen is used as a pharmacokinetic probe for gastric emptying because its absorption occurs almost exclusively in the proximal small intestine. If a drug delays stomach emptying, acetaminophen Cmax falls and Tmax lengthens.

In a phase 1 crossover study, participants received 1,000 mg of oral acetaminophen before and during tirzepatide 5 mg treatment 7. Results showed acetaminophen Cmax was reduced by approximately 50%, and Tmax shifted from roughly 0.5 hours to 1.5 hours 7. Total exposure (AUC) decreased by 12% to 17%, meaning the drug was still absorbed but more slowly and at a lower peak.

For patients using acetaminophen for acute pain relief, this matters. A 50% reduction in peak blood levels may produce inadequate analgesia during the first hour after dosing. Taking acetaminophen on an empty stomach at least 30 to 60 minutes before a meal may partially offset this delay, though no formal study has tested this strategy with tirzepatide specifically.

NSAIDs absorbed in the stomach (like aspirin) might be less affected, but no dedicated interaction studies exist for these agents with tirzepatide. Until data emerge, treat all oral analgesics as potentially subject to delayed absorption.

Warfarin, Levothyroxine, and Narrow Therapeutic Index Drugs

Drugs with narrow therapeutic indexes are the highest-risk category for any interaction that alters absorption kinetics. Even modest changes in Cmax or AUC can push these medications into subtherapeutic or toxic ranges.

Warfarin. No formal drug-drug interaction study has been conducted between tirzepatide and warfarin 3. Warfarin is absorbed in the stomach and upper small intestine, making it susceptible to gastric emptying delays. The FDA recommends increased INR monitoring when initiating Zepbound in patients on warfarin and during all dose escalation steps. Test INR weekly for the first 4 weeks after any tirzepatide dose change.

Levothyroxine. Thyroid hormone replacement depends on consistent, fasting-state absorption in the proximal small intestine. Data from the GLP-1 receptor agonist class (including liraglutide and semaglutide) show delayed levothyroxine absorption with this drug class 8. The American Thyroid Association recommends taking levothyroxine 60 minutes before any other medication or food 9. Patients starting Zepbound should have TSH levels rechecked 6 to 8 weeks after initiation and after each dose escalation.

Digoxin, phenytoin, and cyclosporine are additional narrow therapeutic index drugs for which no formal interaction data exist with tirzepatide. Apply the same principle: monitor drug levels more frequently during tirzepatide titration.

Statins, ACE Inhibitors, and Other Common Co-Medications

Patients prescribed Zepbound for chronic weight management often take medications for hypertension, dyslipidemia, and gastroesophageal reflux. The good news: population pharmacokinetic analyses from the SURPASS and SURMOUNT programs found no clinically meaningful changes in the exposure of atorvastatin, lisinopril, or omeprazole when co-administered with tirzepatide 3.

Atorvastatin AUC changed by less than 5% in these pooled analyses. Lisinopril exposure was similarly unaffected 3. These drugs have wide therapeutic windows, so even a 10% to 15% shift in Cmax would rarely produce clinical consequences.

Proton pump inhibitors (PPIs) present a theoretical concern. PPIs require an acidic environment for activation, and delayed gastric emptying prolongs gastric acid contact time. This could theoretically increase PPI activation. No adverse signals have emerged from clinical trials, but prescribers should be aware of the mechanism.

SSRIs and SNRIs have not been formally studied with tirzepatide. Most are well absorbed throughout the gastrointestinal tract with wide therapeutic margins. Consider monitoring for changes in efficacy or side effects during tirzepatide titration, particularly with medications that have steep dose-response curves.

Metformin and Other Oral Diabetes Medications

Metformin is absorbed primarily in the small intestine and has a bioavailability of roughly 50% to 60% under normal conditions 10. Delayed gastric emptying could theoretically reduce metformin peak levels, but SURPASS trial data showed no clinically relevant impact on metformin pharmacokinetics when combined with tirzepatide 3. The combination was used throughout the SURPASS program without dose adjustments for metformin.

SGLT2 inhibitors (empagliflozin, dapagliflozin) were also co-administered in SURPASS trials. No pharmacokinetic interactions were reported. These agents work in the kidney, not the gut, so delayed gastric emptying is irrelevant to their mechanism of action. The combination of tirzepatide plus an SGLT2 inhibitor is increasingly common in practice, and no dose modification is needed for either drug.

DPP-4 inhibitors (sitagliptin, linagliptin) overlap mechanistically with tirzepatide since both increase incretin activity. The American Diabetes Association's 2024 Standards of Care recommend discontinuing DPP-4 inhibitors when initiating a GLP-1 or dual GIP/GLP-1 receptor agonist because of redundant mechanisms and no added benefit 11.

Clinical Monitoring Framework for Prescribers

No single guideline document covers all tirzepatide drug interactions in one place. The following framework, synthesized from the FDA label and published pharmacokinetic data, provides a practical monitoring protocol.

Tier 1 (active intervention required): Oral contraceptives, insulin, sulfonylureas. These require either dose changes, method switches, or added barrier contraception before tirzepatide initiation.

Tier 2 (enhanced monitoring): Warfarin (check INR weekly for 4 weeks after each dose change), levothyroxine (recheck TSH at 6 to 8 weeks), digoxin, phenytoin, cyclosporine, and any drug with a narrow therapeutic index.

Tier 3 (watch and document): Acetaminophen, NSAIDs, SSRIs, SNRIs, and other oral medications with wide therapeutic windows. Counsel patients that onset of action may be slower for acute-use medications. No routine lab changes needed.

Tier 4 (no action needed): Statins, ACE inhibitors, ARBs, SGLT2 inhibitors, metformin, PPIs at standard doses. Population PK data support no dose adjustments.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity notes that "for patients on multiple oral medications, clinicians should review the complete medication list before initiating any GLP-1 or dual-agonist therapy and monitor for altered drug efficacy during the titration period" 12.

Each dose escalation of tirzepatide (from 2.5 mg to 5 mg, 5 mg to 10 mg, 10 mg to 15 mg) temporarily intensifies gastric emptying delay. Repeat monitoring at each step for Tier 1 and Tier 2 medications. Once a patient has been stable on a given dose for 8 or more weeks, the gastric emptying effect plateaus and monitoring can return to standard intervals.